Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Return on Equity (2016 - 2025)

Avalo Therapeutics filings provide 11 years of Return on Equity readings, the most recent being 0.01% for Q4 2025.

  • On a quarterly basis, Return on Equity changed 0.0% to 0.01% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.01%, a 0.0% change, with the full-year FY2025 number at 0.01%, changed 0.0% from a year prior.
  • Return on Equity hit 0.01% in Q4 2025 for Avalo Therapeutics, up from 0.01% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.03% in Q2 2023 to a low of 0.06% in Q3 2023.
  • Median Return on Equity over the past 5 years was 0.0% (2022), compared with a mean of 0.0%.
  • Biggest five-year swings in Return on Equity: dropped -6bps in 2023 and later grew 4bps in 2024.
  • Avalo Therapeutics' Return on Equity stood at 0.0% in 2021, then soared by 2086bps to 0.0% in 2022, then plummeted by -17701bps to 0.03% in 2023, then soared by 84bps to 0.0% in 2024, then plummeted by -97bps to 0.01% in 2025.
  • The last three reported values for Return on Equity were 0.01% (Q4 2025), 0.01% (Q3 2025), and 0.0% (Q2 2025) per Business Quant data.